Infections Deaths in the PLATO Trial
Background Cardiovascular benefits of aggressive dual antiplatelet therapy may be associated with extra risks including bleeding, cancer, and infections discovered first for prasugrel in the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel (TRITON)...
Guardado en:
Autores principales: | Victor Serebruany, Jean-Francois Tanguay |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Georg Thieme Verlag KG
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/21f0efbfbda84e639dc973214dd37e3d |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Ticagrelor vs. Clopidogrel After Complex Percutaneous Coronary Intervention in Patients With Stable Coronary Artery Disease
por: Ziwei Xi, et al.
Publicado: (2021) -
Assessment of Impact of Patient Recruitment Volume on Risk Profile, Outcomes, and Treatment Effect in a Randomized Trial of Ticagrelor Versus Prasugrel in Acute Coronary Syndromes
por: Gjin Ndrepepa, et al.
Publicado: (2021) -
Recruitment Practices in Multicenter Randomized Clinical Trials: Time for a Relook
por: Prakriti Gaba, et al.
Publicado: (2021) -
Causes of Death in People With Cardiovascular Disease: A UK Biobank Cohort Study
por: Michael Drozd, et al.
Publicado: (2021) -
Impact of Routine Platelet Reactivity Testing with VerifyNow Assay on Antiplatelet Choice After Percutaneous Coronary Intervention
por: Mshelbwala FS, et al.
Publicado: (2020)